All News

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

The first oncology therapeutic biosimilars are now available in the United States.

A binational team of investigators at the University of California, Davis, has conducted the first comprehensive study to examine the risk factors for Rocky Mountain spotted fever in Mexicali, Mexico. They found that citywide, just 1 in 1000 ticks was infected with the disease, but in certain neighborhoods, about 1 in 10 ticks was infected.

According to the National Institute of Diabetes and Digestive and Kidney Diseases, more than 661,000 Americans have kidney failure.

Individuals with HIV maintained similar rates of viral suppression after switching from a 3-drug regimen to the 2-drug regimen of dolutegravir plus lamivudine.

Photobiomodulation therapy found effective for the prevention of oral mucositis caused by radiation therapy.

Top news of the day from across the health care landscape.

A new legislation signed by Governor Ned Lamont has brought cause for celebration among Connecticut pharmacists and patients alike in the fight for drug pricing transparency.

Insulin levels in the mother's body during fetal development or possible changes to the mother's DNA expression passed to her offspring may increase the risk for developing leukemia.

Merck’s antibacterial drug injection—a combination of imipenem, cilastatin and relebactam (Recarbrio) —is indicated for adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

A Bluetooth-enabled, nanochannel drug delivery system administers controlled doses based on patients’ therapeutic needs.

Top news of the day from across the health care landscape.

Acute flaccid myelitis (AFM) is a rare polio-like condition that can cause limb weakness, and it mostly occurs in young children.

Mergers and acquisitions among health care giants are causing massive disruption in specialty pharmacy.

Top news of the day from across the health care landscape.

Research highlights the importance of reaching non-white and younger populations with skin cancer prevention messages.

Data from the BEACON CRC trial show encorafenib, binimetinib, and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer.